ENT (Otorhinolaryngology) in Texas

Ampcare manufactures and distributes the Effective Swallowing Protocol (ESP), a neuromuscular electrical stimulation (NMES) system combined with resistive exercise and restorative posture devices for dysphagia (swallowing disorder) treatment. The ESP protocol targets swallow anatomy, provides airway resistance, and uses perturbation science to accelerate airway closure time, reducing aspiration risk. The system features patented electrode design with larger contact surfaces to minimize patient discomfort ("hot spots") compared to competing NMES devices. Ampcare positions cost-effectiveness as a competitive advantage, citing $1.63 per-treatment electrode cost. The company offers comprehensive speech-language pathology (SLP) training through ASHA CE-accredited certification workshops available in live classroom (4–8 hours in-person), on-demand, and hybrid formats. Training covers anatomy, physiology, muscle fiber recruitment, electrotherapy principles, and evidence supporting the ESP protocol. Ampcare targets speech-language pathologists and swallow therapy clinicians in rehabilitation and outpatient settings. The product is supported by published research demonstrating functional improvements in swallow safety and patient outcomes.

Eosera Inc manufactures over-the-counter ear care solutions for consumers and healthcare settings. The company's product portfolio includes EAR PAIN MD (4% lidocaine ear pain relief drops), WAX BLASTER MD (manual at-home ear irrigation system with reusable tips and drops for earwax removal), and EAR ITCH MD (botanical spray for dry, itchy ears). Products are formulated to address common ear conditions including earwax impaction, ear pain, and irritation from allergies, hearing aids, earbuds, and skin conditions such as eczema and psoriasis. Clinical data demonstrates EAR WAX MD cleared earwax impaction in 86% of users and reduced associated symptoms in 82%, with 100% user satisfaction. EAR PAIN MD is physician-recommended and marketed as the #1 OTC topical ear pain relief brand. The company offers dedicated pediatric formulations across all product lines. Eosera positions itself as an ear care expert focused on accessible, non-prescription solutions for ear health maintenance and symptom relief.

Scivita Medical Technology Co., Ltd. is a minimally invasive surgical device manufacturer headquartered in Suzhou, China. The company designs and manufactures single-use and reusable endoscopic instruments and systems for gynecology, urology, orthopedics, thoracic surgery, ENT, general surgery, respiratory, and gastroenterology applications. Product portfolio includes single-use video arthroscopes, transforaminal endoscopes, flexible and semi-flexible hysteroscopes, rigid and flexible cystoscopes, and ureteroscopes. The company also produces the Omni Power System for minimally invasive surgical procedures and operates a Dual-scope Platform integrating rigid and flexible endoscopy. Scivita maintains a CNAS-accredited testing center for full-chain endoscope validation and quality assurance. The company serves global markets through international presence and clinical education programs. Manufacturing capabilities encompass design, assembly, quality testing, and sterilization of single-use surgical instruments and integrated endoscopic systems. The company has demonstrated growth through new product launches and international conference presentations, including recent debuts at major urology and surgical conferences.

Ototronix manufactures the MAXUM System, a minimally invasive middle ear implant designed to provide superior hearing outcomes compared to conventional hearing aids. The system consists of a small magnetic titanium implant placed on the ossicles (middle ear bones) and an advanced external sound processor worn in or behind the ear canal. Using electromagnetic energy to directly stimulate the inner ear (cochlea), the MAXUM delivers cleaner, crisper sound quality with reduced feedback and occlusion effects. The implant procedure is performed as an outpatient surgery under local anesthetic in approximately 30 minutes. Key clinical advantages include feedback elimination, minimized occlusion (hollow-sounding voice), improved sound clarity, and enhanced speech understanding in challenging acoustic environments. The MAXUM addresses limitations of traditional hearing aids, particularly for patients experiencing feedback, occlusion discomfort, or inadequate amplification.